Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 16;19(1):153.
doi: 10.1186/s12903-019-0850-1.

Treatment of recurrent aphthous stomatitis (RAS; aphthae; canker sores) with a barrier forming mouth rinse or topical gel formulation containing hyaluronic acid: a retrospective clinical study

Domenico Dalessandri  1 , Francesca Zotti  2 , Laura Laffranchi  1 , Marco Migliorati  3 , Gaetano Isola  4 , Stefano Bonetti  1 , Luca Visconti  1
Affiliations

Treatment of recurrent aphthous stomatitis (RAS; aphthae; canker sores) with a barrier forming mouth rinse or topical gel formulation containing hyaluronic acid: a retrospective clinical study

Domenico Dalessandri et al. BMC Oral Health. .

Abstract

Background: Use of hyaluronic acid-based products has become a valuable alternative to drug-based approaches in the treatment of recurrent aphthous stomatitis (RAS). The presented study aimed to investigate the effect of a barrier forming hyaluronic acid containing mouth wash or a topical gel formulation on the healing of RAS and patient's quality of life.

Methods: For this single-center retrospective study, medical records of the Dental School of the University of Brescia were screened for adult and systemically health patients suffering from minor recurrent aphthous stomatitis (RAS) and treated with either a barrier forming, hyaluronic acid containing mouth wash (GUM® AftaClear® rinse) or a topical gel (GUM® AftaClear® gel) in 2015. All patients fulfilling the in-/exclusion criteria and presenting full data sets on lesion diameter, lesion color, as well as pain perception for baseline (day 0) and 4 and 7 days after treatment were enrolled into the presented study.

Results: Out of 60 screened patients, a total of 20 patients treated with the Rinse formulation and 25 treated with the Gel formulation were eligible for the enrollment into this study. Both groups showed equal distribution in patient's age, sex and presented a similar mean lesion size (3.0 ± 1.0 mm), lesion color distribution as well as pain perception at baseline. All patients showed significant normalization of lesion color, reduction of pain, and lesion dimension within the course of their treatment. After 7 days, the mean percentage of lesion reduction was highly significant for both groups attaining 77.4 ± 30.1% in the Rinse group and 81.2 ± 23.1% in the Gel group with a complete lesion closure obtained in 60 and 56% of the cases, respectively. However, a significant (p < 0.05) higher percentage of lesions in the Gel group (72%) compared to the Rinse group (40%) showed an improvement in lesion size already after 3 days.

Conclusions: Within the limitation of retrospective design, it can be concluded that both the barrier forming hyaluronic acid containing mouth rinse as well as the topical gel formulation are effective in the treatment of minor recurrent aphthous stomatitis (RAS), with a trend for an earlier healing onset for the topical Gel formulation.

Keywords: Barrier forming; Hyaluronic acid; Recurrent aphthous stomatitis; Rinse; Topical gel.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Distribution of recurrent aphthous stomatitis (RAS) types at baseline
Fig. 2
Fig. 2
Mean aphthous lesion diameter [mm] and mean percentage of lesion closure [%]
Fig. 3
Fig. 3
Overall distribution of percentage of lesion closure after 3 and 7 days (all sites)
Fig. 4
Fig. 4
Degree of lesion closure for Rinse and Gel group after 3 and 7 days
Fig. 5
Fig. 5
Distribution of lesion color grades at baseline and after 3 and 7 days
Fig. 6
Fig. 6
Distribution of reported pain intensity at baseline and after 3 and 7 days
Fig. 7
Fig. 7
Percentage of patients with eating and drinking disturbance at baseline and after 3 and 7 days
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Woods MA, Mohammad AR, Turner JE, Mincer HH. Oral ulcerations. Quintessence Int. 1990;21:141–151. - PubMed
    1. Taylor LJ, Bagg J, Walker DM, Peters TJ. Increased production of tumour necrosis factor by peripheral blood leukocytes in patients with recurrent oral aphthous ulceration. J Oral Pathol Med. 1992;21:21–25. doi: 10.1111/j.1600-0714.1992.tb00963.x. - DOI - PubMed
    1. Ship JA. Recurrent aphthous stomatitis. An update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996;81:141–147. doi: 10.1016/S1079-2104(96)80403-3. - DOI - PubMed
    1. Thakrar P, Chaudhry SI. Oral ulceration: an overview of diagnosis and management. Prim Dent J. 2016;5:30–33. - PubMed
    1. Scully C, Porter S. Oral mucosal disease: recurrent aphthous stomatitis. Br J Oral Maxillofac Surg. 2008;46:198–206. doi: 10.1016/j.bjoms.2007.07.201. - DOI - PubMed

Publication types